Muratore M, Santacesaria G, Quarta E, Calcagnile F, Cosentino L, Muratore L
Department of Rheumatology, A. Galateo Hospital, S. Cesario di Lecce, Italy.
Int J Clin Pharmacol Res. 2000;20(3-4):61-4.
Steroid therapy is the third most common cause of osteoporosis, after loss of gonad function and senescence. The aim of the present study was to evaluate the protective action of clodronate on bone mass loss induced by steroid therapy. Sixty patients with bronchial asthma receiving either fluticasone (250 mg x 4/day) or beclomethasone (250 mg x 4/day) inhaled corticosteroid treatment were enrolled. Half the patients received combination treatment with clodronate (100 mg i.m./14 days), for a total period of 12 months. All patients were evaluated at baseline and at the end of treatment for bone mineral density (BMD) and calcium/phosphor metabolism parameters (kalemia, kaluria, phosphoremia, phosphaturia, alkaline phosphatase and hydroxyprolinuria over a 24-h period). The results of this preliminary study confirm the protective influence of clodronate on bone mass loss, as documented by the increment in mean values in BMD reported at the end of treatment compared with baseline values.
类固醇疗法是继性腺功能丧失和衰老之后，导致骨质疏松的第三大常见原因。本研究的目的是评估氯膦酸盐对类固醇疗法引起的骨质流失的保护作用。招募了60例接受氟替卡松（250毫克×4/天）或倍氯米松（250毫克×4/天）吸入性皮质类固醇治疗的支气管哮喘患者。一半患者接受氯膦酸盐（100毫克肌肉注射/14天）联合治疗，为期12个月。在基线和治疗结束时对所有患者进行骨矿物质密度（BMD）和钙/磷代谢参数（血钾、尿钾、血磷、尿磷、碱性磷酸酶和24小时尿羟脯氨酸）评估。这项初步研究的结果证实了氯膦酸盐对骨质流失的保护作用，治疗结束时报告的BMD平均值与基线值相比有所增加，证明了这一点。
